Non-invasive biomarkers fibrotest-actitest for replacing invasive liver biopsy: The need for change and action

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 2, 2007, Pages 173-174

  Munteanu, Mona ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ANTIVIRAL THERAPY; CLINICAL TRIAL; DATA BASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EDITORIAL; GENOTYPE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MORTALITY; PROGNOSIS; ROMANIA;

BIOLOGICAL MARKERS; BIOPSY, NEEDLE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 34347341839     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
2. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004; 10: 1-6.
3. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
4. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastroenterol. 2006; 101: 547-555.
5. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006; 44: 686-693.
6. Grigorescu M, Rusu M, Neculoiu D, et al. The FibroTest value in discriminating between insiginificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointestin Liver Dis 2007;16: 31-37.
7. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 2002; 36: S161-S172.
8. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.
9. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38; 1449-1457.
10. Poynard T, Halfon P, Castera L,et al and FibroPaca Group. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.. Aliment Pharmacol Ther 2007;25:733-739
11. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-1355.
12. T. Poynard, P. Halfon, L. Castera, et al. Prevalence of each fibrosis stage is a major factor of variability when assessing the area under the roc curves in the evaluation of liver fibrosis markers. EASL 2007 9 (abstr.)
13. Messous D, Munteanu M, Morra R, et al. Time impact of serum storage temperature on stability of important liver enzymes and proteins, and on FibroTest-ActiTest results. Clin Chim Acta 2005; 335: 400.